SchizophreniafuNEEGNCT07856368
Neuronavigated rTMS for Treatment-Resistant Auditory Hallucinations
A study testing Neuronavigated repetitive transcranial magnetic stimulation (rTMS) in people with Schizophrenia and Auditory Verbal Hallucinations, run by Psychiatric University Hospital, Zurich at 1 site in Switzerland.
Trial summary
Auditory verbal hallucinations (AVH), such as hearing voices in the absence of an external sound source, are a common and distressing symptom of schizophrenia. In some patients, hallucinations persist despite treatment with antipsychotic medication. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Schizophrenia, Auditory Verbal Hallucinations
- What is being tested?
- Neuronavigated repetitive transcranial magnetic stimulation (rTMS)
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 siteSwitzerland
- Study dates
- 11 Jun 2026to Nov 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Written informed consent provided prior to participation
- Age 18 to 65 years
- Medication-resistant auditory hallucinations, defined as:
- At least two adequate trials of antipsychotic medication
- At least one of these trials with an atypical antipsychotic medication
- At least five episodes of auditory hallucinations per day during the preceding month
Show all 10Show fewer
- Stable antipsychotic medication for at least 6 weeks
- Current treatment at the Psychiatric University Hospital Zurich (PUK), either in an outpatient clinic, day clinic, or inpatient ward
- Sufficient knowledge of German to understand the study procedures and assessments
- Ability to follow study procedures
Who cannot join
- Contraindications to TMS treatment, including cochlear implants, metallic devices close to the TMS coil, history of stroke, head injury, or seizures/epilepsy
- History of epileptic convulsive seizures or epileptiform potentials in previous EEG examinations
- TMS treatment within the 3 months preceding study inclusion
- Known severe hypersensitivity or severe adverse reaction to TMS
- Pregnancy or breastfeeding
- Intention to become pregnant during the study
Show all 16Show fewer
- Major somatic comorbidities, such as renal failure, hepatic dysfunction, heart failure, or cardiovascular disease
- Current treatment with any drug that lowers the seizure threshold
- Known or suspected non-compliance, drug abuse, or alcohol abuse
- Vulnerable subjects (children, pregnant women, elderly persons)
- Inability to follow study procedures, for example due to language problems, psychological disorder, dementia, or other conditions interfering with participation
- Participation in another study involving investigational treatment within the 30 days preceding study inclusion or during the present study
- Current electroconvulsive therapy (ECT)
- Previous enrollment in the present study
- Investigator, family member of the investigator, employee, or other dependent person
- Contraindications or limitations related to the medical device as specified in the instructions for use
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Switzerland1 site, 1 recruiting
- Recruiting
Psychiatric University Hospital Zurich
Zurich, 8032
Tobias Welt, Dr. med., 0041 58 384 93 40, tobias.welt@pukzh.ch
Sebastian Olbrich, Prof. Dr. med., 0041 58 384 26 37, sebastian.olbrich@pukzh.ch
About this study
Official title: Functional Neuronavigated EEG and TMS-treatment of Chronic Acoustic Hallucinations
Auditory verbal hallucinations (AVH), such as hearing voices in the absence of an external sound source, are a common and distressing symptom of schizophrenia. In some patients, hallucinations persist despite treatment with antipsychotic medication. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique that may reduce auditory hallucinations by decreasing activity in brain regions involved in auditory and language processing.
This randomized, double-blind, sham-controlled study will investigate whether individualized, neuronavigated inhibitory rTMS can reduce persistent auditory verbal hallucinations. Forty adults with medication-resistant auditory hallucinations will be randomly assigned to receive either active rTMS or sham stimulation.
Read more
For each participant, the stimulation target in the primary auditory cortex will be individually identified using electroencephalography (EEG), acoustic evoked potentials, and magnetic resonance imaging (MRI)-based neuronavigation. Participants will receive two rTMS sessions per day for five consecutive days. The severity of auditory hallucinations will be assessed before and after treatment and at a 28-day follow-up.
The study will also investigate whether treatment is associated with changes in brain activity and functional connectivity measured by EEG, including changes in the P300 event-related potential.
- Conditions
- Schizophrenia, Auditory Verbal Hallucinations
- Being tested
- Neuronavigated repetitive transcranial magnetic stimulation (rTMS), Sham repetitive transcranial magnetic stimulation (rTMS)
- Keywords
- Auditory Verbal Hallucinations, Treatment-Resistant Hallucinations, Repetitive Transcranial Magnetic Stimulation, rTMS, Neuronavigation, Electroencephalography, EEG, Auditory Evoked Potentials, Functional Connectivity, P300
- Medical subject headings
- Schizophrenia, Hallucinations
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Neuronavigated repetitive transcranial magnetic stimulation (rTMS)Device
Individualized neuronavigated inhibitory rTMS is applied to the primary auditory cortex. The individual stimulation target is determined using EEG-based auditory evoked potentials and MRI-based neuronavigation. Stimulation is delivered at 1 Hz on five consecutive days, with a total of 12,000 magnetic pulses administered over the treatment course.
Sham repetitive transcranial magnetic stimulation (rTMS)Device
Sham stimulation is administered using the same neuronavigation procedures and treatment schedule as active rTMS. A sham coil visually and acoustically resembling the active coil is used but does not deliver active magnetic stimulation.
| Study group | Role | What they receive |
|---|---|---|
| Active rTMS | Experimental | Participants receive individualized, neuronavigated inhibitory rTMS targeting the primary auditory cortex. The stimulation target is individually determined using EEG-based auditory evoked potentials and MRI-based neuronavigation. Treatment is administered twice daily for five consecutive days. Receives: Device: Neuronavigated repetitive transcranial magnetic stimulation (rTMS) |
| Sham rTMS | Sham comparator | Participants undergo the same treatment schedule and neuronavigation procedures as the active rTMS group using a sham coil that is visually and acoustically similar to the active coil but does not deliver active magnetic stimulation. Receives: Device: Sham repetitive transcranial magnetic stimulation (rTMS) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline in Auditory Vocal Hallucination Rating Scale (AVHRS) Score Immediately After Treatment
Change from baseline in auditory hallucination severity assessed with the Auditory Vocal Hallucination Rating Scale (AVHRS), a structured interview assessing multiple characteristics of auditory hallucinations, including frequency, duration, location, loudness, negative content, distress, interference with daily life, perceived control, anxiety, and interference with thinking.
Measured: Baseline to immediately after completion of the 5-day treatment period
Secondary outcomes (19)
Change From Baseline in Auditory Vocal Hallucination Rating Scale (AVHRS) Score at Day 28
Change from baseline in auditory hallucination severity assessed with the Auditory Vocal Hallucination Rating Scale (AVHRS), a structured interview assessing multiple characteristics of auditory hallucinations, including frequency, duration, location, loudness, negative content, distress, interference with daily life, perceived control, anxiety, and interference with thinking.
Measured: Baseline to Day 28 after completion of treatment
Change From Baseline in PSYRATS Auditory Hallucinations Subscale Score Immediately After Treatment
Change from baseline in the Auditory Hallucinations subscale of the Psychotic Symptom Rating Scales (PSYRATS). The subscale consists of 11 items scored from 0 to 4, yielding a total score from 0 to 44. Higher scores indicate greater auditory hallucination severity.
Measured: Baseline to immediately after completion of the 5-day treatment period
Change From Baseline in PSYRATS Delusions Subscale Score Immediately After Treatment
Change from baseline in the Delusions subscale of the Psychotic Symptom Rating Scales (PSYRATS). The subscale consists of 6 items scored from 0 to 4, yielding a total score from 0 to 24. Higher scores indicate greater delusion severity.
Measured: Baseline to immediately after completion of the 5-day treatment period
Change From Baseline in PSYRATS Combined Score Immediately After Treatment
Change from baseline in the combined Psychotic Symptom Rating Scales (PSYRATS) score, calculated as the sum of the Auditory Hallucinations and Delusions subscale scores. The combined score ranges from 0 to 68, with higher scores indicating greater overall psychotic symptom severity.
Measured: Baseline to immediately after completion of the 5-day treatment period
Change From Baseline in PSYRATS Auditory Hallucinations Subscale Score at Day 28
Change from baseline in the Auditory Hallucinations subscale of the Psychotic Symptom Rating Scales (PSYRATS). The subscale consists of 11 items scored from 0 to 4, yielding a total score from 0 to 44. Higher scores indicate greater auditory hallucination severity.
Measured: Baseline to Day 28 after completion of treatment
Change From Baseline in PSYRATS Delusions Subscale Score at Day 28
Change from baseline in the Delusions subscale of the Psychotic Symptom Rating Scales (PSYRATS). The subscale consists of 6 items scored from 0 to 4, yielding a total score from 0 to 24. Higher scores indicate greater delusion severity.
Measured: Baseline to Day 28 after completion of treatment
Change From Baseline in PSYRATS Combined Score at Day 28
Change from baseline in the combined Psychotic Symptom Rating Scales (PSYRATS) score, calculated as the sum of the Auditory Hallucinations and Delusions subscale scores. The combined score ranges from 0 to 68, with higher scores indicating greater overall psychotic symptom severity.
Measured: Baseline to Day 28 after completion of treatment
Change From Baseline in Auditory Vocal Hallucination Rating Scale Questionnaire (AVHRS-Q) Total Score Immediately After Treatment
Change from baseline in the total score of the Auditory Vocal Hallucination Rating Scale Questionnaire (AVHRS-Q), a self-report measure assessing characteristics and severity of auditory vocal hallucinations. Higher scores indicate greater severity of auditory vocal hallucinations.
Measured: Baseline to immediately after completion of the 5-day treatment period
Change From Baseline in Auditory Vocal Hallucination Rating Scale Questionnaire (AVHRS-Q) Total Score at Day 28
Change from baseline in the total score of the Auditory Vocal Hallucination Rating Scale Questionnaire (AVHRS-Q), a self-report measure assessing characteristics and severity of auditory vocal hallucinations. Higher scores indicate greater severity of auditory vocal hallucinations.
Measured: Baseline to Day 28 after completion of treatment
Change From Baseline in Self-assessment of Auditory Verbal Hallucinations (SAVH) Total Score Immediately After Treatment
Change from baseline in the total score of the Self-assessment of Auditory Verbal Hallucinations (SAVH), a 9-item self-report measure assessing auditory verbal hallucinations during the preceding week. Each item is scored from 0 to 5, yielding a total score from 0 to 45. Higher scores indicate greater severity of auditory verbal hallucinations.
Measured: Baseline to immediately after completion of the 5-day treatment period
Change From Baseline in Self-assessment of Auditory Verbal Hallucinations (SAVH) Total Score at Day 28
Change from baseline in the total score of the Self-assessment of Auditory Verbal Hallucinations (SAVH), a 9-item self-report measure assessing auditory verbal hallucinations during the preceding week. Each item is scored from 0 to 5, yielding a total score from 0 to 45. Higher scores indicate greater severity of auditory verbal hallucinations.
Measured: Baseline to Day 28 after completion of treatment
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score Immediately After Treatment
Change from baseline in illness severity assessed using the Clinical Global Impression-Severity (CGI-S) scale. CGI-S is rated from 1 to 7, with higher scores indicating greater illness severity.
Measured: Baseline to immediately after completion of the 5-day treatment period
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score at Day 28
Change from baseline in illness severity assessed using the Clinical Global Impression-Severity (CGI-S) scale. CGI-S is rated from 1 to 7, with higher scores indicating greater illness severity.
Measured: Baseline to Day 28 after completion of treatment
Clinical Global Impression-Improvement (CGI-I) Score Immediately After Treatment
Overall change in clinical condition assessed using the Clinical Global Impression-Improvement (CGI-I) scale. CGI-I is rated from 1 to 7, where 1 indicates very much improved, 4 indicates no change, and 7 indicates very much worse.
Measured: Immediately after completion of the 5-day treatment period
Clinical Global Impression-Improvement (CGI-I) Score at Day 28
Overall change in clinical condition assessed using the Clinical Global Impression-Improvement (CGI-I) scale. CGI-I is rated from 1 to 7, where 1 indicates very much improved, 4 indicates no change, and 7 indicates very much worse.
Measured: Day 28 after completion of treatment
Change From Baseline in Auditory P300 Parameters Immediately After Treatment
Change from baseline in auditory P300 event-related potential parameters measured by EEG during an auditory Oddball paradigm. P300 amplitude and latency elicited by target stimuli will be evaluated and compared between baseline and post-treatment recordings.
Measured: Baseline to immediately after completion of the 5-day treatment period
Change From Baseline in Auditory P300 Parameters at Day 28
Change from baseline in auditory P300 event-related potential parameters measured by EEG during an auditory Oddball paradigm. P300 amplitude and latency elicited by target stimuli will be evaluated and compared between baseline and Day-28 recordings.
Measured: Baseline to Day 28 after completion of treatment
Change From Baseline in EEG Functional Connectivity Immediately After Treatment
Change from baseline in functional brain connectivity assessed using EEG and source localization with low-resolution electromagnetic tomography (LORETA). Treatment-related changes in functional connectivity between cortical brain regions will be evaluated by comparing baseline and post-treatment EEG recordings.
Measured: Baseline to immediately after completion of the 5-day treatment period
Change From Baseline in EEG Functional Connectivity at Day 28
Change from baseline in functional brain connectivity assessed using EEG and source localization with low-resolution electromagnetic tomography (LORETA). Treatment-related changes in functional connectivity between cortical brain regions will be evaluated by comparing baseline and Day-28 EEG recordings.
Measured: Baseline to Day 28 after completion of treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Oct 2026
- Study start11 Jun 2026
- Primary completionNov 2028 (estimated)
- Study completionNov 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SchizophreniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants are randomized in a 1:1 ratio to one of two parallel study arms receiving either active neuronavigated inhibitory rTMS or sham stimulation. Both groups undergo identical study procedures and assessments.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Psychiatric University Hospital, Zurich
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Sebastian Olbrich, Prof. Dr. med., Study director, Psychiatrische Universitätsklinik Zürich
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07856368
- Sponsor's protocol ID
- fuNEEG
- Other IDs
- Bangerter-Rhyner-Foundation
- Acronym
- fuNEEG
- Status last verified
- Sep 2026
- First submitted
- 23 Sep 2026
- Last updated
- 2 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data are not planned to be made publicly available. Potential reuse of pseudonymized data may be considered in accordance with participant consent and applicable ethical and data protection requirements.
Study at a glance
From the registry record, last updated by the sponsor on 2 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Functional Neuronavigated EEG and TMS-treatment of Chronic Acoustic Hallucinations
- ClinicalTrials.gov ID
- NCT07856368
- Acronym / sponsor ID
- fuNEEG / fuNEEG
- Conditions
- Schizophrenia, Auditory Verbal Hallucinations
- Keywords
- Auditory Verbal Hallucinations, Treatment-Resistant Hallucinations, Repetitive Transcranial Magnetic Stimulation, rTMS, Neuronavigation, Electroencephalography, EEG, Auditory Evoked Potentials
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Psychiatric University Hospital, ZurichUniversity, hospital or other
- Study start
- 11 Jun 2026 (actual)
- Primary completion
- Nov 2028 (estimated)
- Study completion
- Nov 2028 (estimated)
- First posted
- 2 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Auditory verbal hallucinations (AVH), such as hearing voices in the absence of an external sound source, are a common and distressing symptom of schizophrenia. In some patients, hallucinations persist despite treatment with antipsychotic medication. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique that may reduce auditory hallucinations by decreasing activity in brain regions involved in auditory and language processing.
This randomized, double-blind, sham-controlled study will investigate whether individualized, neuronavigated inhibitory rTMS can reduce persistent auditory verbal hallucinations. Forty adults with medication-resistant auditory hallucinations will be randomly assigned to receive either active rTMS or sham stimulation.
For each participant, the stimulation target in the primary auditory cortex will be individually identified using electroencephalography (EEG), acoustic evoked potentials, and magnetic resonance imaging (MRI)-based neuronavigation. Participants will receive two rTMS sessions per day for five consecutive days. The severity of auditory hallucinations will be assessed before and after treatment and at a 28-day follow-up.
The study will also investigate whether treatment is associated with changes in brain activity and functional connectivity measured by EEG, including changes in the P300 event-related potential.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Participants are randomized in a 1:1 ratio to one of two parallel study arms receiving either active neuronavigated inhibitory rTMS or sham stimulation. Both groups undergo identical study procedures and assessments.
| Arm | Type | Receives |
|---|---|---|
| Active rTMS | Experimental | Device: Neuronavigated repetitive transcranial magnetic stimulation (rTMS)Participants receive individualized, neuronavigated inhibitory rTMS targeting the primary auditory cortex. The stimulation target is individually determined using EEG-based auditory evoked potentials and MRI-based neuronavigation. Treatment is administered twice daily for five consecutive days. |
| Sham rTMS | Sham comparator | Device: Sham repetitive transcranial magnetic stimulation (rTMS)Participants undergo the same treatment schedule and neuronavigation procedures as the active rTMS group using a sham coil that is visually and acoustically similar to the active coil but does not deliver active magnetic stimulation. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Written informed consent provided prior to participation
- Age 18 to 65 years
- Medication-resistant auditory hallucinations, defined as:
- Current treatment at the Psychiatric University Hospital Zurich (PUK), either in an outpatient clinic, day clinic, or inpatient ward
- Sufficient knowledge of German to understand the study procedures and assessments
Key exclusion criteria (16 listed)
- Contraindications to TMS treatment, including cochlear implants, metallic devices close to the TMS coil, history of stroke, head injury, or seizures/epilepsy
- History of epileptic convulsive seizures or epileptiform potentials in previous EEG examinations
- TMS treatment within the 3 months preceding study inclusion
- Known severe hypersensitivity or severe adverse reaction to TMS
- Pregnancy or breastfeeding
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Neuronavigated repetitive transcranial magnetic stimulation (rTMS)Individualized neuronavigated inhibitory rTMS is applied to the primary auditory cortex. The individual stimulation target is determined using EEG-based auditory evoked potentials and MRI-based neuronavigation. Stimulation is delivered at 1 Hz on five consecutive days, with a total of 12,000 magnetic pulses administered over the treatment course. | Device | Active rTMS |
| Sham repetitive transcranial magnetic stimulation (rTMS)Sham stimulation is administered using the same neuronavigation procedures and treatment schedule as active rTMS. A sham coil visually and acoustically resembling the active coil is used but does not deliver active magnetic stimulation. | Device | Sham rTMS |
Primary outcome
Change From Baseline in Auditory Vocal Hallucination Rating Scale (AVHRS) Score Immediately After Treatment
Time frame: Baseline to immediately after completion of the 5-day treatment period
Change from baseline in auditory hallucination severity assessed with the Auditory Vocal Hallucination Rating Scale (AVHRS), a structured interview assessing multiple characteristics of auditory hallucinations, including frequency, duration, location, loudness, negative content, distress, interference with daily life, perceived control, anxiety, and interference with thinking.
19 secondary outcomes
Change From Baseline in Auditory Vocal Hallucination Rating Scale (AVHRS) Score at Day 28
Time frame: Baseline to Day 28 after completion of treatment
Change From Baseline in PSYRATS Auditory Hallucinations Subscale Score Immediately After Treatment
Time frame: Baseline to immediately after completion of the 5-day treatment period
Change From Baseline in PSYRATS Delusions Subscale Score Immediately After Treatment
Time frame: Baseline to immediately after completion of the 5-day treatment period
Change From Baseline in PSYRATS Combined Score Immediately After Treatment
Time frame: Baseline to immediately after completion of the 5-day treatment period
Change From Baseline in PSYRATS Auditory Hallucinations Subscale Score at Day 28
Time frame: Baseline to Day 28 after completion of treatment
Change From Baseline in PSYRATS Delusions Subscale Score at Day 28
Time frame: Baseline to Day 28 after completion of treatment
Change From Baseline in PSYRATS Combined Score at Day 28
Time frame: Baseline to Day 28 after completion of treatment
Change From Baseline in Auditory Vocal Hallucination Rating Scale Questionnaire (AVHRS-Q) Total Score Immediately After Treatment
Time frame: Baseline to immediately after completion of the 5-day treatment period
Change From Baseline in Auditory Vocal Hallucination Rating Scale Questionnaire (AVHRS-Q) Total Score at Day 28
Time frame: Baseline to Day 28 after completion of treatment
Change From Baseline in Self-assessment of Auditory Verbal Hallucinations (SAVH) Total Score Immediately After Treatment
Time frame: Baseline to immediately after completion of the 5-day treatment period
Change From Baseline in Self-assessment of Auditory Verbal Hallucinations (SAVH) Total Score at Day 28
Time frame: Baseline to Day 28 after completion of treatment
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score Immediately After Treatment
Time frame: Baseline to immediately after completion of the 5-day treatment period
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score at Day 28
Time frame: Baseline to Day 28 after completion of treatment
Clinical Global Impression-Improvement (CGI-I) Score Immediately After Treatment
Time frame: Immediately after completion of the 5-day treatment period
Clinical Global Impression-Improvement (CGI-I) Score at Day 28
Time frame: Day 28 after completion of treatment
Change From Baseline in Auditory P300 Parameters Immediately After Treatment
Time frame: Baseline to immediately after completion of the 5-day treatment period
Change From Baseline in Auditory P300 Parameters at Day 28
Time frame: Baseline to Day 28 after completion of treatment
Change From Baseline in EEG Functional Connectivity Immediately After Treatment
Time frame: Baseline to immediately after completion of the 5-day treatment period
Change From Baseline in EEG Functional Connectivity at Day 28
Time frame: Baseline to Day 28 after completion of treatment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Oct 2026.
- Individual participant dataSharing planned: No. Individual participant data are not planned to be made publicly available. Potential reuse of pseudonymized data may be considered in accordance with participant consent and applicable ethical and data protection requirements.
Related trials for Schizophrenia
RecruitingPhase 1
A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
Schizophrenia
Recruiting
A Relation Between Craving Induction and Treatment Response in Deep Transcranial Magnetic Stimulation (dTMS) for Reducing Antipsychotic-induced Weight Gain in Schizophrenia
Schizophrenia, Antipsychotic Induced Weight Gain
Recruiting
Impact of Cerebellar TMS on Brain and Cognitive Functions in Schizophrenia: a Pilot Study
Schizophrenia, Cerebellar Function
Recruiting
tACS for Working Memory in Schizophrenia
Schizophrenia, Working Memory
Recruiting
Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium: Study 3
Schizophrenia / Schizoaffective Disorder, SCHIZOPHRENIA 1 (Disorder)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Sebastian Olbrich, Prof. Dr. med. study director
Psychiatrische Universitätsklinik Zürich
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Neuronavigated repetitive transcranial magnetic stimulation (rTMS) in people with Schizophrenia and Auditory Verbal Hallucinations, run by Psychiatric University Hospital, Zurich at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Tobias Welt, MD (0041 58 389 93 40, tobias.welt@pukzh.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline in Auditory Vocal Hallucination Rating Scale (AVHRS) Score Immediately After Treatment (time frame: Baseline to immediately after completion of the 5-day treatment period). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2026.